Bioventus (BVS) Depreciation & Amortization (CF) (2020 - 2026)

Bioventus has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 5.56% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $46.4 million (down 6.62% YoY), and the FY2025 full-year result was $47.0 million, down 5.13% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $11.2 million, down from $11.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $16.9 million in Q4 2022, with the low at $11.2 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $13.0 million across 5 years, with a median of $12.4 million in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 73.71% — and 2024, when it retreated 28.46%.
• Bioventus' Depreciation & Amortization (CF) stood at $16.9 million in 2022, then dropped by 26.43% to $12.5 million in 2023, then decreased by 0.48% to $12.4 million in 2024, then decreased by 5.73% to $11.7 million in 2025, then decreased by 4.18% to $11.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $11.2 million (Q1 2026), $11.7 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.